DK1070065T3 - Azabicykliske 5-HT1 receptorligander - Google Patents

Azabicykliske 5-HT1 receptorligander

Info

Publication number
DK1070065T3
DK1070065T3 DK99945686T DK99945686T DK1070065T3 DK 1070065 T3 DK1070065 T3 DK 1070065T3 DK 99945686 T DK99945686 T DK 99945686T DK 99945686 T DK99945686 T DK 99945686T DK 1070065 T3 DK1070065 T3 DK 1070065T3
Authority
DK
Denmark
Prior art keywords
azabicyclic
receptor ligands
ligands
receptor
Prior art date
Application number
DK99945686T
Other languages
Danish (da)
English (en)
Inventor
Gene Michael Bright
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of DK1070065T3 publication Critical patent/DK1070065T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Luminescent Compositions (AREA)
DK99945686T 1998-04-09 1999-03-18 Azabicykliske 5-HT1 receptorligander DK1070065T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8123798P 1998-04-09 1998-04-09
PCT/IB1999/000457 WO1999052907A1 (en) 1998-04-09 1999-03-18 Azabicyclic 5ht1 receptor ligands

Publications (1)

Publication Number Publication Date
DK1070065T3 true DK1070065T3 (da) 2003-11-24

Family

ID=22162936

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99945686T DK1070065T3 (da) 1998-04-09 1999-03-18 Azabicykliske 5-HT1 receptorligander

Country Status (40)

Country Link
US (2) US6525048B1 (cs)
EP (1) EP1070065B1 (cs)
JP (1) JP3496759B2 (cs)
KR (1) KR100378931B1 (cs)
CN (1) CN1117092C (cs)
AP (1) AP1175A (cs)
AR (1) AR015751A1 (cs)
AT (1) ATE248838T1 (cs)
AU (1) AU749254B2 (cs)
BG (1) BG104915A (cs)
BR (1) BR9909522A (cs)
CA (1) CA2327782A1 (cs)
CO (1) CO5080727A1 (cs)
CZ (1) CZ20003684A3 (cs)
DE (1) DE69910997T2 (cs)
DK (1) DK1070065T3 (cs)
DZ (1) DZ2756A1 (cs)
EA (1) EA003400B1 (cs)
ES (1) ES2204154T3 (cs)
HR (1) HRP20000653A2 (cs)
HU (1) HUP0102400A3 (cs)
ID (1) ID26086A (cs)
IL (1) IL138629A0 (cs)
IS (1) IS5641A (cs)
MA (1) MA26619A1 (cs)
MY (1) MY133390A (cs)
NO (1) NO20005004L (cs)
NZ (1) NZ507010A (cs)
OA (1) OA11496A (cs)
PA (1) PA8469101A1 (cs)
PE (1) PE20000413A1 (cs)
PL (1) PL343408A1 (cs)
PT (1) PT1070065E (cs)
SK (1) SK14782000A3 (cs)
TN (1) TNSN99056A1 (cs)
TR (1) TR200002932T2 (cs)
TW (1) TW555758B (cs)
WO (1) WO1999052907A1 (cs)
YU (1) YU59400A (cs)
ZA (1) ZA992596B (cs)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6231833B1 (en) * 1999-08-05 2001-05-15 Pfizer Inc 2,7-substituted octahydro-1H-pyrido[1,2-A]pyrazine derivatives as ligands for serotonin receptors
UA62015C2 (en) 1998-12-28 2003-12-15 Pfizer Prod Inc Benzoizoxazol derivatives, a pharmaceutical composition (variants) based thereon (variants) and a method for treatment (variants)
EE05315B1 (et) 1999-09-03 2010-08-16 Eli Lilly And Company Dapoksetiini v?i selle farmatseutiliselt vastuv?etava soola kasutamine ravimi valmistamiseks, mis on ette n„htud imetajal esineva seksuaalse funktsioonih„ire ravimiseks v?i m?jutamiseks
GB2362826A (en) * 2000-06-02 2001-12-05 Lilly Co Eli A pharmaceutical composition comprising a serotonin transport inhibitor and a serotonin recptor antagonist
US6855729B2 (en) * 2001-02-20 2005-02-15 Timothy G. Dinan Treatment of fibromyalgia and related fatigue syndromes using antagonists or partial agonists of 5HT1a receptors
CN100389115C (zh) * 2003-03-12 2008-05-21 辉瑞产品公司 吡啶氧基甲基和苯并异唑氮杂二环衍生物
JP2007519705A (ja) * 2004-01-29 2007-07-19 ファイザー・プロダクツ・インク Ｃｎｓ障害を治療するための非定型抗精神病薬とアミノメチルピリジルオキシメチル／ベンゾイソオキサゾールアザビシクロ誘導体の組合せ
JP4559749B2 (ja) * 2004-02-16 2010-10-13 あすか製薬株式会社 ピペラジニルピリジン誘導体
AR049478A1 (es) 2004-03-25 2006-08-09 Solvay Pharm Bv Un procedimiento para la preparacion de 3-amino-8-(1-piperazinil)-2h-1-benzopiran-2-ona. sales e hidratos y composiciones farmaceuticas.
AR048112A1 (es) 2004-03-25 2006-03-29 Solvay Pharm Bv Derivados de 1-(2h-1-benzopiran-2-on-8-il)-piperazina para el tratamiento de dolor
CA2571555A1 (en) * 2004-06-22 2006-01-05 Pfizer Products Inc. Diazabicyclic histamine-3 receptor antagonists
US8685924B2 (en) 2004-08-25 2014-04-01 Takeda Pharmaceutical Company Limited Preventives/remedies for stress urinary incontinence and method of screening the same
BRPI0514793A (pt) * 2004-09-10 2008-06-24 Pfizer Prod Inc uso de derivados azabicìclicos de benzisoxazol e piridiloximetila na preparação de um medicamento para o tratamento de distúrbios cognitivos
RU2417082C2 (ru) * 2009-07-14 2011-04-27 Учреждение Российской Академии Наук Институт Физиологически Активных Веществ Ран (Ифав Ран) Средство для восстановления утраченной памяти в норме и патологии у пациентов всех возрастных групп на основе n, n'-замещенных 3, 7-диазабицикло[3.3.1]нонанов, фармацевтическая композиция на его основе и способ ее применения
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2020087031A1 (en) 2018-10-26 2020-04-30 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
WO2020183011A1 (en) 2019-03-14 2020-09-17 Institut Curie Htr1d inhibitors and uses thereof in the treatment of cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5106849A (en) * 1988-05-24 1992-04-21 American Home Products Corporation Use of aryl- and heteroaryl piperazinyl carboxamides in the treatment of various central nervous system disorders
WO1990008148A1 (en) * 1989-01-23 1990-07-26 Pfizer Inc. Bis-aza-bicyclic anxiolytic agents
US5157034A (en) * 1991-02-27 1992-10-20 Pfizer Inc. Neuroleptic perhydro-1H-pyrido[1,2-a]pyrazines
DK0607163T3 (da) * 1991-09-25 1997-03-17 Pfizer Neuroleptiske 2-substituerede perhydro-1-H-pyrido- 1,2-a pyraziner
US5262428A (en) * 1992-03-13 1993-11-16 Wake Forest University Biologically active tropane derivatives
DK0646116T3 (da) * 1992-06-16 1999-12-27 Pfizer Fremgangsmåde og mellemprodukter til fremstilling af bis-aza-bicycliske anxiolytiske midler
GB9410512D0 (en) * 1994-05-25 1994-07-13 Smithkline Beecham Plc Novel treatment
WO1996010570A1 (en) * 1994-09-30 1996-04-11 Pfizer Inc. NEUROLEPTIC 2,7-DISUBSTITUTED PERHYDRO-1H-PYRIDO[1,2-a]PYRAZINES
US5614523A (en) * 1995-01-17 1997-03-25 Eli Lilly And Company Compounds having effects on serotonin-related systems

Also Published As

Publication number Publication date
JP3496759B2 (ja) 2004-02-16
PE20000413A1 (es) 2000-05-25
AR015751A1 (es) 2001-05-16
KR100378931B1 (ko) 2003-04-07
EA003400B1 (ru) 2003-04-24
ATE248838T1 (de) 2003-09-15
IL138629A0 (en) 2001-10-31
ID26086A (id) 2000-11-23
DE69910997T2 (de) 2004-05-19
HUP0102400A3 (en) 2002-10-28
YU59400A (sh) 2003-10-31
AU749254B2 (en) 2002-06-20
CN1305477A (zh) 2001-07-25
BR9909522A (pt) 2000-12-19
PL343408A1 (en) 2001-08-13
NO20005004D0 (no) 2000-10-04
JP2002511469A (ja) 2002-04-16
MY133390A (en) 2007-11-30
AP1175A (en) 2003-06-04
BG104915A (en) 2001-07-31
EP1070065A1 (en) 2001-01-24
US6887905B2 (en) 2005-05-03
US20030181458A1 (en) 2003-09-25
NZ507010A (en) 2003-05-30
CA2327782A1 (en) 1999-10-21
CZ20003684A3 (cs) 2002-03-13
PT1070065E (pt) 2003-12-31
TW555758B (en) 2003-10-01
EA200000910A1 (ru) 2001-04-23
ZA992596B (en) 2000-10-08
HUP0102400A2 (hu) 2001-11-28
DE69910997D1 (de) 2003-10-09
SK14782000A3 (sk) 2002-06-04
CO5080727A1 (es) 2001-09-25
NO20005004L (no) 2000-11-27
HRP20000653A2 (en) 2001-04-30
EP1070065B1 (en) 2003-09-03
AU3268799A (en) 1999-11-01
TR200002932T2 (tr) 2001-01-22
IS5641A (is) 2000-09-26
OA11496A (en) 2004-05-14
HK1035719A1 (en) 2001-12-07
PA8469101A1 (es) 2000-09-29
AP9901502A0 (en) 1999-06-30
ES2204154T3 (es) 2004-04-16
DZ2756A1 (fr) 2003-09-15
CN1117092C (zh) 2003-08-06
MA26619A1 (fr) 2004-12-20
KR20010042527A (ko) 2001-05-25
WO1999052907A1 (en) 1999-10-21
US6525048B1 (en) 2003-02-25
TNSN99056A1 (fr) 2005-11-10

Similar Documents

Publication Publication Date Title
NO20012411D0 (no) Pyrrolidin-derivater-CCR-3-reseptorantagonister
MA25403A1 (fr) Ligandes de recepteur de melanocortine
CY2010003I2 (el) Αγωνιστες των βητα-2 αδρενεργικων υποδοχεων
ATE280157T1 (de) 4-aroyl-piperidin-ccr-3 rezeptor antagonisten iii
DE69812096D1 (de) Neuropeptid y rezeptorantagonisten
DE59904239D1 (de) Sitzvorrichtung
DE69734833D1 (de) Vitronektin rezeptor antagonisten
IS5706A (is) Adenosín A3 viðtakastillar
NO20023895L (no) Anilin-avledete ligander for thyroid-reseptoren
DK1070065T3 (da) Azabicykliske 5-HT1 receptorligander
ID24726A (id) Antagonis-antagonis reseptor trombin
DE59904577D1 (de) Metallocenkomplexe
NO20013997D0 (no) Reseptoranalyse
ID24162A (id) Antagonis-antagonis reseptor vitronektin
TR199501389A2 (tr) Adesyon reseptörü antagonistleri (karsitlari).
ID28802A (id) Turunan indol
NO20014961D0 (no) Integrin-reseptor-ligander
NO20021295D0 (no) Nikotinsyreacetylcholin-reseptor
DE69908330D1 (de) 5-heteroaryl-substituierte indole
DE69431672D1 (de) Adrenergischer rezeptor
SI1070065T1 (en) Azabicyclic 5ht1 receptor ligands
BR1100444A (pt) ligantes de receptor de 5-ht4 de 1-fenilalcanona
TR199601082A3 (tr) Entegrin reseptör antagonistleri.
GB9815373D0 (en) Receptor ligands
IT1294264B1 (it) Sedile basculante